The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

CASSIOPET study: Is PET-CT a surrogate prognostic marker in transplant eligible patients with NDMM?

Dec 12, 2019

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, FR, answers the following question about the results of the CASSIOPET study: Is PET-CT a surrogate prognostic marker in transplant eligible patients with newly diagnosed multiple myeloma?

Philippe Moreau discusses the phase III, randomized CASSIOPET study, that looked at the effect of daratumumab in the context of stem cell transplantation. He discusses the efficacy of the drug regimen in the study arms. He also talks about the results of a trial that assessed the predictive value of PET-CT on patient outcomes.

CASSIOPET study: Is PET-CT a surrogate prognostic marker in transplant eligible patients with NDMM?